RxDoctor Payments Data

Ajay Shah, MD

Cardiovascular Disease · Eatontown, NJNPI 1144486523

Payments from drug & device makers

$10,387in general payments, 2019–2025

Across 587 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Novartis$1K
  • Amgen$697
  • Johnson & Johnson$690
  • AstraZeneca$677
  • Irhythm Technologies, Inc.$576
  • plus $5K from 43 others

What the payments were for

  • Food & beverage$10,387100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,387 in reported general payments places this provider in the 75th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$309,677
Medicare patients
1,708
Services billed
4,395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban228$284,774
XareltoRivaroxaban55$68,101
EntrestoSacubitril/Valsartan42$56,941
Repatha SureclickEvolocumab22$23,128
MultaqDronedarone Hcl20$22,631
FarxigaDapagliflozin Propanediol24$22,113
JardianceEmpagliflozin15$16,282
Rosuvastatin Calcium473$8,296
VascepaIcosapent Ethyl14$5,573
Metoprolol Succinate273$4,587
Nebivolol Hcl65$4,451
Losartan Potassium218$2,240
Atorvastatin Calcium183$1,991
Diltiazem 24hr Er (Cd)Diltiazem Hcl49$1,916
Flecainide Acetate42$1,842

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$362$284,774228 claims
Johnson & JohnsonXarelto$690$68,10155 claims
NovartisEntresto$1,098$56,94142 claims
Sanofi-aventis U.S. LLCMultaq$85$22,63120 claims
AstraZenecaFarxiga$677$22,11324 claims
Boehringer IngelheimJardiance$361$16,28215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Eatontown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →